Pulmatrix reported a significant decline in cash and cash equivalents to $1.4 million in Q3 2026, down from $4.1 million at year-end 2025, while general and administrative expenses rose. The company reiterated its focus on the pending merger with Eos SENOLYTIX, expected to close by year-end, which is the primary driver of current operations and financial positioning.
Pulmatrix's Q3 2026 filing reveals a concerning cash burn, with cash and cash equivalents dropping to $1.4 million from $4.1 million at the end of 2025. This significant decline, coupled with rising general and administrative expenses, indicates ongoing operational costs without substantial revenue generation. The company's low R&D spending reflects its current strategic pivot towards the merger with Eos SENOLYTIX, which is expected to close by year-end. For traders, the short-term implication is increased uncertainty around Pulmatrix's financial stability leading up to the merger, with potential for dilution or further capital raises if the merger is delayed or terms are unfavorable. The long-term outlook hinges entirely on the successful completion and strategic benefits of the Eos SENOLYTIX merger, which remains the key opportunity and risk.